Seragon Pharmaceuticals' Series A Round

Seragon Pharmaceuticals raised a round of funding on October 16, 2013.

Seragon is focused on developing new treatments for estrogen-driven cancers based on its Selective Estrogen Receptor Degrader (SERD) platform. Seragon Pharmaceuticals' orally active selective estrogen…

Articles about Seragon Pharmaceuticals' Series A Round: